CY1121660T1 - Φαρμακευτικη συνθεση για τη θεραπεια των hiv λοιμωξεων - Google Patents

Φαρμακευτικη συνθεση για τη θεραπεια των hiv λοιμωξεων

Info

Publication number
CY1121660T1
CY1121660T1 CY20191100564T CY191100564T CY1121660T1 CY 1121660 T1 CY1121660 T1 CY 1121660T1 CY 20191100564 T CY20191100564 T CY 20191100564T CY 191100564 T CY191100564 T CY 191100564T CY 1121660 T1 CY1121660 T1 CY 1121660T1
Authority
CY
Cyprus
Prior art keywords
treatment
pharmaceutical composition
hiv infections
hiv
ingredients
Prior art date
Application number
CY20191100564T
Other languages
English (en)
Inventor
Vikram Singkh PUNIYA
Gennady Andreevich Batyunin
Natalya Yurievna MALYKH
Original Assignee
Aktsionernoe Obschestvo "Farmasyntez"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49957619&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121660(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aktsionernoe Obschestvo "Farmasyntez" filed Critical Aktsionernoe Obschestvo "Farmasyntez"
Publication of CY1121660T1 publication Critical patent/CY1121660T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Η εφεύρεση σχετίζεται με το πεδίο της χημικής και φαρμακευτικής βιομηχανίας, ειδικά με μια φαρμακευτική σύνθεση για την θεραπεία μιας λοίμωξης από HIV• περιέχει τουλάχιστον έναν αναστολέα της πρωτεάσης του ΗIV ως δραστικό συστατικό, καθώς και φαρμακευτικά αποδεκτά έκδοχα με συγκεκριμένη ποσοτική αναλογία των συστατικών. Επιπλέον, η εφεύρεση ανήκει στη διαδικασία της παραγωγής της και σε μια μέθοδο θεραπείας. Η φαρμακευτική σύνθεση σύμφωνα με την εφεύρεση έχει αυξημένη βιοδιαθεσιμότητα και βελτιωμένες τεχνολογικές ιδιότητες σε σύγκριση με το πρωτότυπο φάρμακο.
CY20191100564T 2012-12-29 2019-05-29 Φαρμακευτικη συνθεση για τη θεραπεια των hiv λοιμωξεων CY1121660T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2012158141/15A RU2505286C1 (ru) 2012-12-29 2012-12-29 Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
PCT/RU2013/000817 WO2014104929A1 (ru) 2012-12-29 2013-09-19 Фармацевтическая композиция для лечения вич-инфекции

Publications (1)

Publication Number Publication Date
CY1121660T1 true CY1121660T1 (el) 2020-07-31

Family

ID=49957619

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100564T CY1121660T1 (el) 2012-12-29 2019-05-29 Φαρμακευτικη συνθεση για τη θεραπεια των hiv λοιμωξεων

Country Status (18)

Country Link
US (1) US10493034B2 (el)
EP (1) EP2939665B1 (el)
CN (1) CN104884050A (el)
CA (1) CA2896710C (el)
CY (1) CY1121660T1 (el)
DK (1) DK2939665T3 (el)
EA (1) EA029586B1 (el)
ES (1) ES2729568T3 (el)
HR (1) HRP20190882T1 (el)
HU (1) HUE043694T2 (el)
LT (1) LT2939665T (el)
PL (1) PL2939665T3 (el)
PT (1) PT2939665T (el)
RS (1) RS58837B1 (el)
RU (1) RU2505286C1 (el)
SI (1) SI2939665T1 (el)
TR (1) TR201908007T4 (el)
WO (1) WO2014104929A1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105194687A (zh) * 2015-10-22 2015-12-30 浙江医药高等专科学校 沙喹那韦或其甲磺酸盐的环糊精包合物制备方法
WO2017086835A1 (ru) * 2015-11-17 2017-05-26 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция, обладающая терапевтическим эффектом в отношении демиелинизирующих заболеваний (варианты)
RU2616267C1 (ru) * 2016-01-25 2017-04-13 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма индинавира немедленного высвобождения и способ ее получения

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US20050048112A1 (en) * 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
PE20080422A1 (es) * 2006-08-10 2008-04-28 Cipla Ltd Composicion solida antirretroviral de administracion oral
PA8809601A1 (es) * 2007-12-24 2009-07-23 Cipla Ltd Combinación anti-retroviral
WO2009087410A2 (en) * 2008-01-11 2009-07-16 Cipla Limited Solid pharmaceutical dosage form
US8501961B2 (en) * 2008-07-09 2013-08-06 Purdue Research Foundation HIV protease inhibitors and methods for using
US20110034489A1 (en) * 2009-07-31 2011-02-10 Ranbaxy Laboratories Limited Solid dosage forms of hiv protease inhibitors
WO2012164575A2 (en) * 2011-05-27 2012-12-06 Hetero Research Foundation Amorphous ritonavir co-precipitated
EP2802354A4 (en) * 2012-01-09 2015-07-29 Virginia Tech Intell Prop CELLULOSE DERIVATIVES FOR INHIBITING THE CRYSTALLIZATION OF MEDIALLY SOLUBLE DRUGS IN WATER
EP2819668A4 (en) * 2012-03-01 2015-07-29 Hetero Research Foundation COMPOSITIONS OF RITONAVIR
WO2014184553A1 (en) * 2013-05-15 2014-11-20 Cipla Limited Pharmaceutical antiretroviral compositions

Also Published As

Publication number Publication date
HRP20190882T1 (hr) 2019-09-20
ES2729568T3 (es) 2019-11-04
PL2939665T3 (pl) 2020-01-31
WO2014104929A1 (ru) 2014-07-03
CA2896710C (en) 2019-03-26
DK2939665T3 (da) 2019-06-11
EP2939665B1 (en) 2019-03-20
CA2896710A1 (en) 2014-07-03
HUE043694T2 (hu) 2019-09-30
US20150297526A1 (en) 2015-10-22
EP2939665A1 (en) 2015-11-04
US10493034B2 (en) 2019-12-03
RU2505286C1 (ru) 2014-01-27
PT2939665T (pt) 2019-06-14
CN104884050A (zh) 2015-09-02
EP2939665A4 (en) 2016-06-01
EA201500710A1 (ru) 2015-10-30
RS58837B1 (sr) 2019-07-31
LT2939665T (lt) 2019-07-25
EA029586B1 (ru) 2018-04-30
SI2939665T1 (sl) 2019-08-30
TR201908007T4 (tr) 2019-06-21

Similar Documents

Publication Publication Date Title
CY1118661T1 (el) Φαρμακευτικη συνθεση, φαρμακευτικη δοσολογικη μορφη, διαδικασια για την παρασκευη τους, μεθοδοι για αντιμετωπιση και χρησεις αυτων
EA201892838A1 (ru) Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их
EA201890124A1 (ru) Новые гидроксикислотные производные, способ их получения и фармацевтические композиции, содержащие их
EA201890123A1 (ru) Новые аминокислотные производные, способ их получения и фармацевтические композиции, содержащие их
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
CY1121660T1 (el) Φαρμακευτικη συνθεση για τη θεραπεια των hiv λοιμωξεων
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
EA201892173A1 (ru) Фармацевтический состав палбоциклиба и способ его получения
EA201401292A3 (ru) Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их
EA201590862A1 (ru) Фармацевтические композиции
CY1119957T1 (el) Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
PE20140255A1 (es) Tableta dispersable en forma oral
TR201821116A2 (tr) POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
IN2013MU03583A (el)
CY1124782T1 (el) Φαρμακοτεχνικες μορφες μακρας δρασης
IN2014MN02236A (el)
IN2013MU00711A (el)
BR112017000898A2 (pt) oritavancina de alta pureza e método de produção da mesma
EA201790495A1 (ru) Фармацевтические композиции длительного действия
BR112017024727A2 (pt) cocristal, composição farmacêutica, método de tratamento de uma doença em um indivíduo e processo de produção de um cocristal
EA201691490A1 (ru) Фармацевтическая композиция, содержащая бринзоламид
EA202090014A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA201890906A1 (ru) ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
CY1124893T1 (el) Φαρμακευτικο μeιγμα μαροπιταντης